查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953439

月經症候群 (PMS) 和月經健康補充劑市場 - 全球產業規模、佔有率、趨勢、機會和預測：按產品類型、適應症、劑型、最終用途、地區和競爭格局分類，2021-2031 年

Premenstrual Syndrome and Menstrual Health Supplements Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented Product Type, By Indication, By Formulation, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球月經症候群 (PMS) 和月經健康補充劑市場預計將從 2025 年的 214.5 億美元成長到 2031 年的 296.8 億美元，複合年成長率達到 5.56%。

這些膳食補充劑通常由特殊的營養保健品組合藥物構成，包含維生素、礦物質和植物萃取物，旨在緩解與月經週期相關的生理和心理症狀。市場成長的主要驅動力是全球月經症候群發生率的上升，以及消費者健康管理方式轉向預防性、非藥物療法的根本性轉變。與新劑型等暫時性的市場趨勢不同，這些促進因素代表著對長期生殖健康的結構性承諾，以及對傳統止痛藥天然替代品的持續需求。

市場概覽
預測期 2027-2031
市場規模：2025年 214.5億美元
市場規模：2031年 296.8億美元
複合年成長率：2026-2031年 5.56%
成長最快的細分市場 月經症候群（PMS）
最大的市場 北美洲

市場擴張的一大障礙是複雜的法規環境。由於缺乏統一的健康聲明支持標準，如果製造商沒有嚴格的臨床證據，就無法宣傳特定的療效。這種全球監管的不一致性常常為產品分銷和行銷合規帶來挑戰。例如，人們越來越依賴針對特定症狀的成分。負責任營養委員會 (CRN) 的報告顯示，到 2024 年，鎂（一種用於緩解月經和情緒波動的關鍵營養素）在膳食補充劑消費者中的使用量增加了 23%。

市場促進因素

意識提升以及圍繞月經健康的污名化現象的消除，正在從根本上改變市場動態，鼓勵人們公開討論那些過去被視為正常或被忽視的症狀。這種文化演變正將月經護理的重點從簡單的衛生護理轉向全面的管理，並鼓勵女性積極尋求營養解決方案以維持健康和工作效率。健康素養的提高與產品消費之間的直接關聯日益明顯，消費者正從一般保健產品轉向針對特定症狀的產品。例如，The Vitamin Shoppe 於 2024 年 6 月發布的《2024 年健康與保健趨勢報告》顯示，專為經月經症候群 (PMS) 設計的配方產品的銷量較上年度成長了 12%，表明消費者對針對特定症狀的管理需求日益成長。

同時，消費者對天然、有機和植物來源成分的偏好日益成長，推動了潔淨標示膳食補充劑的發展，因為他們逐漸遠離合成藥物。這一趨勢青睞植物萃取物和生物利用度高的礦物質，與傳統止痛藥相比，這些成分被視為更安全的長期荷爾蒙調節替代品。根據Holland & Barrett於2024年11月發布的《2025年健康趨勢報告》，鎂甘氨酸（一種因其在月經溫和吸收和肌肉放鬆功效而備受推崇的礦物質）的在線搜尋量激增180%。這種對高品質非藥物替代品的需求正在推動整個品類的擴張。 Haleon於2025年2月發布的《2024年全年業績報告》顯示，其維生素、礦物質和膳食補充劑部門的有機收入增加了7.6%。

市場挑戰

複雜的法規環境和不一致的健康聲明驗證標準，對全球月經症候群 (PMS) 和月經健康補充劑市場的擴張構成了重大障礙。膳食補充劑法規的顯著區域差異意味著製造商在產品配方和行銷傳播的標準化方面面臨巨大挑戰。在許多司法管轄區，法律禁止產品在未經廣泛且昂貴的臨床檢驗的情況下，做出諸如緩解月經或減輕荷爾蒙引起的情緒波動等特定療效聲明。這導致品牌無法充分向消費者宣傳植物來源和營養配方產品的有效性，最終限制了銷售量和市場滲透率。

在消費者對特殊功能性成分日益成長的興趣下，這種監管限制尤其具有挑戰性。根據責任營養委員會 (CRN) 2024 年的一份報告，睡茄（一種常用於緩解壓力和調節情緒的植物萃取物）的使用率已達到膳食補充劑使用者的 8%。儘管消費者對這類天然替代品的需求顯而易見，但嚴格的證據規則限制了製造商明確宣稱其產品具有與月經症候群 (PMS) 相關的直接功效，從而阻礙了產品差異化。因此，市場難以將消費者對這類成分日益成長的認知轉化為更廣泛的品類成長，因為消費者往往不願意購買那些被迫做出模糊或淡化健康聲明的產品。

市場趨勢

週期性營養補充的興起正在推動產品開發的根本性轉變。消費者越來越傾向於選擇針對卵泡期、排卵期、黃體期和月經期的特定階段營養方案，而非傳統的綜合維他命。這種趨勢超越了簡單的營養補充，推動了對先進的28天套裝的需求，這些套裝能夠根據即時激素變化同步釋放營養成分，例如在黃體期補充鎂以改善情緒，或在月經補充鐵。從被動因應症狀到主動最佳化荷爾蒙水平的轉變，也反映在消費者對數位化參與度的提升。例如，《The Drum》在2025年1月發表了一篇題為《為什麼女性會轉向TikTok尋求月經建議？品牌在哪裡？ 》的報導，其中指出Google趨勢數據顯示，消費者對週期同步營養補充的興趣同比成長了124%，這表明品牌擁有巨大的機會去教育和吸引這一資訊靈通的群體。

同時，人工智慧驅動的個人化營養計畫的引入正在改變經營模式，透過數據驅動的客製化將偶爾購買者轉化為長期定期訂閱。演算法測試評估個人的症狀模式和生物特徵數據，使製造商能夠針對特定的生殖健康目標（例如更年期過渡或減輕月經症候群 (PMS) 的嚴重程度）客製化精準的每日營養包，從而提升客戶價值感知和客戶維繫。這種技術與健康的融合正在為領導企業帶來顯著的經濟效益。根據 NutraIngredients 2024 年 7 月發表的一篇報導《聯合利華探討健康業務的爆炸式成長》，人工智慧等新興工具的整合，加上對女性健康領域的戰略關注，使得該公司健康與福祉部門的基礎銷售額成長了 20%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球月經症候群 (PMS) 和月經健康補充劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依適應症（圍絕經期、經前症候群）
    • 按劑型（膠囊/錠劑、粉末、軟膠囊、其他）
    • 依最終用途（藥局/藥局、線上銷售管道、銷售管道、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美月經症候群 (PMS) 和月經健康補充劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲月經症候群 (PMS) 和月經健康補充劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區月經症候群（PMS）和月經健康補充劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲月經症候群 (PMS) 及月經健康補充品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲月經症候群 (PMS) 與月經健康補充劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

13. 全球月經症候群 (PMS) 和月經健康補充劑市場：SWOT 分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Herbalife International of America, Inc.
  • Nature's Bounty
  • Amway Corp.
  • GNC Holdings, LLC
  • USANA Health Sciences, Inc
  • GlaxoSmithKline Plc
  • MetP Pharma AG
  • Archer-Daniels-Midland Company
  • Power Gummies
  • Looni

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24094

The Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market is projected to expand from USD 21.45 Billion in 2025 to USD 29.68 Billion by 2031, achieving a compound annual growth rate (CAGR) of 5.56%. These supplements typically consist of specialized nutraceutical formulations containing vitamins, minerals, and botanical extracts intended to alleviate the physiological and psychological symptoms linked to the menstrual cycle. The market's growth is primarily sustained by the increasing global incidence of premenstrual disorders and a fundamental consumer shift toward preventive, non-pharmaceutical health management; unlike fleeting market trends such as new delivery formats, these drivers indicate a structural commitment to long-term reproductive wellness and a persistent demand for natural substitutes to traditional pain medications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 21.45 Billion
Market Size 2031USD 29.68 Billion
CAGR 2026-20315.56%
Fastest Growing SegmentPMS (Premenstrual Syndrome)
Largest MarketNorth America

A major obstacle hindering wider market scalability is the intricate regulatory environment, where inconsistent standards for substantiating health claims prevent manufacturers from advertising specific therapeutic benefits without rigorous clinical proof. This absence of global regulatory alignment frequently creates difficulties in product distribution and marketing compliance. Illustrating the increasing dependence on ingredients that target specific symptoms, the Council for Responsible Nutrition reported in 2024 that the usage of magnesium, a critical nutrient employed to manage menstrual cramps and mood swings, increased to 23 percent among supplement consumers.

Market Driver

The growing consumer awareness and the destigmatization surrounding menstrual health are fundamentally transforming market dynamics by fostering open discussions about symptoms that were historically normalized or ignored. This cultural evolution has shifted the focus of menstrual care from simple hygiene to comprehensive management, encouraging women to proactively seek nutraceutical solutions to maintain their well-being and productivity. A direct link is emerging between this increased health literacy and product consumption, as buyers graduate from general wellness items to targeted remedies; for instance, The Vitamin Shoppe's 'Health & Wellness Trend Report 2024' from June 2024 noted a 12 percent increase in sales of specialized PMS formulas over the previous year, underscoring the rising demand for symptom-specific management.

At the same time, a growing preference for natural, organic, and plant-based ingredients is propelling the development of clean-label supplements as consumers move away from synthetic pharmaceuticals. This trend prioritizes botanical extracts and bioavailable minerals, which are viewed as safer alternatives for long-term hormonal regulation compared to conventional pain relievers. According to Holland & Barrett's 'Wellness Trends Report 2025' released in November 2024, online searches for Magnesium Glycinate-a mineral form valued for its gentle absorption and muscle-relaxing effects during menstruation-surged by 180 percent. This appetite for high-quality, non-pharmacological choices is fueling broader category expansion, as evidenced by Haleon's '2024 Full year results' from February 2025, which reported a 7.6 percent growth in organic revenue for their Vitamins, Minerals and Supplements division.

Market Challenge

The intricate regulatory environment and inconsistent standards regarding the substantiation of health claims create a significant barrier to scalability within the Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market. Since dietary supplement regulations vary widely across different regions, manufacturers encounter major challenges in standardizing product formulations and marketing communications. In numerous jurisdictions, companies are legally prohibited from making specific therapeutic assertions-such as claiming a product alleviates menstrual cramps or reduces hormonal mood swings-without expensive and extensive clinical validation, which prevents brands from fully conveying the efficacy of their botanical and nutrient-based formulas to consumers and ultimately suppresses sales volume and market penetration.

This regulatory constraint is especially restrictive given the growing consumer interest in specialized functional ingredients. As reported by the Council for Responsible Nutrition in 2024, the usage of ashwagandha, a botanical extract frequently used for stress and mood regulation, reached 8 percent among supplement users. Although consumer demand for such natural alternatives is clear, the inability of manufacturers to explicitly label these products with their direct PMS-related benefits due to rigorous substantiation rules hinders product differentiation; consequently, the market faces difficulties in translating this rising ingredient awareness into broader category growth, as consumers often remain reluctant to buy products that are forced to carry vague or diluted health claims.

Market Trends

The widespread adoption of cycle-syncing supplement regimens is fundamentally changing product development, with consumers increasingly moving away from static multivitamins in favor of phase-specific formulations designed for the follicular, ovulatory, luteal, and menstrual phases. This trend goes beyond simple nutrient replenishment, fostering demand for sophisticated 28-day kits that synchronize ingredient release profiles-such as increasing magnesium during the luteal phase for mood support or supplementing iron during menstruation-with real-time hormonal changes. This transition from reactive symptom management to proactive hormonal optimization is highlighted by rising digital engagement; specifically, The Drum reported in January 2025, in the article 'Why are women forced to turn to TikTok for menstrual advice? Where are the brands?', that Google Trends data showed a 124 percent year-on-year increase in consumer interest regarding cycle syncing, indicating a substantial opportunity for brands to educate and engage this informed demographic.

Concurrently, the incorporation of AI-driven personalized nutrition plans is transforming business models by turning sporadic buyers into long-term subscribers through data-based customization. By employing algorithmic quizzes to assess individual symptom patterns and biometric data, manufacturers can now assemble high-precision daily packs that target specific reproductive health objectives, such as managing the perimenopausal transition or PMS severity, thereby increasing perceived value and customer retention. This convergence of technology and health is generating significant financial returns for leading industry players; according to NutraIngredients in July 2024, in the article 'Unilever talks explosive growth of its wellness business', the integration of emerging tools like artificial intelligence combined with a strategic emphasis on women's health categories drove a 20 percent underlying sales growth for the company's Health & Wellbeing Collective.

Key Market Players

  • Herbalife International of America, Inc.
  • Nature's Bounty
  • Amway Corp.
  • GNC Holdings, LLC
  • USANA Health Sciences, Inc
  • GlaxoSmithKline Plc
  • MetP Pharma AG
  • Archer-Daniels-Midland Company
  • Power Gummies
  • Looni

Report Scope

In this report, the Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By Indication

  • Perimenopause
  • PMS

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By Formulation

  • Capsules/Tablets
  • Powder
  • Softgels
  • Other

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By End Use

  • Pharmacies/Drug Stores
  • Online Sales Channel
  • Direct Sales Channel
  • Others

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market.

Available Customizations:

Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Perimenopause, PMS)
    • 5.2.2. By Formulation (Capsules/Tablets, Powder, Softgels, Other)
    • 5.2.3. By End Use (Pharmacies/Drug Stores, Online Sales Channel, Direct Sales Channel, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Formulation
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Formulation
        • 6.3.1.2.3. By End Use
    • 6.3.2. Canada Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Formulation
        • 6.3.2.2.3. By End Use
    • 6.3.3. Mexico Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Formulation
        • 6.3.3.2.3. By End Use

7. Europe Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Formulation
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Formulation
        • 7.3.1.2.3. By End Use
    • 7.3.2. France Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Formulation
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Formulation
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Formulation
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Formulation
        • 7.3.5.2.3. By End Use

8. Asia Pacific Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Formulation
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Formulation
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Formulation
        • 8.3.2.2.3. By End Use
    • 8.3.3. Japan Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Formulation
        • 8.3.3.2.3. By End Use
    • 8.3.4. South Korea Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Formulation
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Formulation
        • 8.3.5.2.3. By End Use

9. Middle East & Africa Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Formulation
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Formulation
        • 9.3.1.2.3. By End Use
    • 9.3.2. UAE Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Formulation
        • 9.3.2.2.3. By End Use
    • 9.3.3. South Africa Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Formulation
        • 9.3.3.2.3. By End Use

10. South America Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Formulation
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Formulation
        • 10.3.1.2.3. By End Use
    • 10.3.2. Colombia Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Formulation
        • 10.3.2.2.3. By End Use
    • 10.3.3. Argentina Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Formulation
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Herbalife International of America, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Nature's Bounty
  • 15.3. Amway Corp.
  • 15.4. GNC Holdings, LLC
  • 15.5. USANA Health Sciences, Inc
  • 15.6. GlaxoSmithKline Plc
  • 15.7. MetP Pharma AG
  • 15.8. Archer-Daniels-Midland Company
  • 15.9. Power Gummies
  • 15.10. Looni

16. Strategic Recommendations

17. About Us & Disclaimer